Leerink Partnrs Has Bearish Outlook for Penumbra Q3 Earnings

Penumbra, Inc. (NYSE:PEN) – Stock analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of Penumbra in a report issued on Tuesday, February 18th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of $0.98 for the quarter, down from their prior forecast of $1.09. The consensus estimate for Penumbra’s current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for Penumbra’s Q4 2025 earnings at $1.11 EPS, FY2027 earnings at $6.86 EPS, FY2028 earnings at $7.92 EPS and FY2029 earnings at $8.96 EPS.

Other equities analysts have also issued research reports about the company. Canaccord Genuity Group boosted their price objective on Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a research note on Wednesday. Citigroup upped their price target on shares of Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Truist Financial raised their price objective on shares of Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. upped their target price on shares of Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Wells Fargo & Company raised their price target on shares of Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $292.64.

Penumbra Stock Up 12.0 %

NYSE PEN opened at $303.55 on Thursday. The stock’s 50 day simple moving average is $256.15 and its 200 day simple moving average is $225.97. Penumbra has a one year low of $148.00 and a one year high of $310.00. The firm has a market cap of $11.65 billion, a PE ratio of 892.79, a price-to-earnings-growth ratio of 1.99 and a beta of 0.53. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.82 and a quick ratio of 3.25.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.73%. The firm had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million.

Insider Buying and Selling

In related news, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total transaction of $40,293.76. Following the transaction, the director now owns 8,530 shares of the company’s stock, valued at $2,058,118.40. This trade represents a 1.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Adam Elsesser sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the completion of the sale, the chief executive officer now directly owns 837,582 shares of the company’s stock, valued at $203,498,922.72. The trade was a 1.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,219 shares of company stock valued at $4,426,439 over the last three months. Company insiders own 5.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC raised its position in shares of Penumbra by 128.1% during the third quarter. Janus Henderson Group PLC now owns 668,873 shares of the company’s stock worth $129,967,000 after purchasing an additional 375,684 shares during the period. Thrivent Financial for Lutherans raised its holdings in Penumbra by 3,832.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company’s stock worth $71,564,000 after buying an additional 358,932 shares during the period. Champlain Investment Partners LLC lifted its stake in Penumbra by 20.6% in the third quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company’s stock valued at $300,786,000 after buying an additional 264,122 shares in the last quarter. Norges Bank bought a new position in Penumbra in the fourth quarter valued at approximately $54,396,000. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in shares of Penumbra by 47.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 707,061 shares of the company’s stock valued at $167,913,000 after buying an additional 227,506 shares during the period. 88.88% of the stock is currently owned by institutional investors.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.